Elevated Blood Pressure Clinical Trial
A Triple Blinded Randomized Controlled Trial of Oral Melatonin in Elevated Blood Pressure Individual (MRCTEBP)
Since, lowering blood pressure (BP) in elevated blood pressure individuals represents an
excellent opportunity to for primary prevention of hypertension (HTN). Therefore, it is
planned to use a safe treatment option - oral melatonin supplementation - associated with
lifestyle interventions according to the American college of cardiology/American heart
association (ACC/AHA) 2013 guideline in elevated blood pressure individuals to mitigate
systolic and diastolic BP and ultimately, to prevent the development of HTN.
Melatonin therapy can lower the systolic and diastolic BP of elevated blood pressure individuals Melatonin can attenuate levels of circulatory biomarkers of Hs- CRP, Cholesterol, LDL-c and triglyceride
Study design: Randomized controlled trial (RCT)
Study population: Elevated blood pressure individuals who present themselves at the outpatient clinics of Tehran Heart Centre(THC) , seeking blood pressure treatment and who have a systolic blood pressure of 120-129 mmHg or a diastolic blood pressure of =80 mmHg.
Treatment groups: Melatonin 3 mg versus placebo
sample size: 160 per group ( 320 overall)
Treatment allocation: After completing informed consent and prior to randomization, all participants undergo complete physical examination and laboratory test. Baseline levels of inflammatory biomarkers and pregnancy test (for women in reproductive age) will be performed. Sleep quality, actual sleep time, and sleep latency will be recorded.
Treatment plan: Three weeks melatonin 3 Mg or placebo one hour before bedtime has been planned. All of the melatonin and placebo capsules will be supplied from a single hospital pharmacy and free of charge to the participants. Melatonin and placebo capsules will be identical. Participants will receive a three weeks supply at the assignment time. Besides, all participants will receive a careful plan of adherence to a heart-healthy diet, regular exercise, instruction for avoidance of tobacco use and maintenance of a healthy body mass index (BMI) according to 2013ACC/ AHA guideline.
Follow up: Three weeks ;
|Source||Tehran University of Medical Sciences|
|Status||Not yet recruiting|
|Start date||January 1, 2019|
|Completion date||January 1, 2020|
|Not yet recruiting||
||Phase 2/Phase 3|